Keyphrases
Abnormal Returns
41%
Active Ingredients
25%
Behavioral Biases
50%
Cosine
25%
Customer-supplier Relationships
25%
Diamond
25%
Drug Approval
25%
Drug Competition
100%
Drug Markets
45%
Entry Decision
35%
Event Data
25%
Firm Experience
41%
Firm Performance
62%
Firm Risk
100%
Firm-level
25%
Focal Firm
50%
Generic Competition
25%
Generic Drugs
100%
Generic Entry
60%
High-tech Industry
25%
High-tech Sector
50%
Idiosyncratic Risk
33%
Impact Area
25%
Impact Event
25%
Lab Experiment
50%
Manufacturing Barriers
100%
Manufacturing Complexity
70%
Market Concentration
35%
Multiple Determinants
35%
Network Metrics
25%
Network Structure
41%
Number of Firms
35%
Percent Increase
50%
Pharmaceutical Industry
35%
Policy Simulation
35%
Pricing Decision
25%
Regulatory Barriers
100%
Regulatory Environment
35%
Review Process
25%
Review Time
25%
Risk Events
41%
Risk Propagation
58%
Risk Source
41%
Shortage Risk
40%
Supply Chain
66%
Supply Chain Risk
50%
Supply Network
83%
Supply Network Structure
100%
Supply Risk Management
25%
Tier-1 Suppliers
41%
Economics, Econometrics and Finance
Event Study
50%
Financial Risk
50%
Firm Performance
50%
Industry
50%
Instrumental Variable Analysis
50%
Market Concentration
100%
Microfoundations
50%
Pharmaceutical Industry
100%
Portfolio Selection
50%
Price
21%
Pricing
50%
Public Health
25%
Relationship Marketing
50%
Retail and Wholesale Occupations
7%
Risk Management
50%
Transnational Corporation
50%
